As 2025 ends, we celebrate the milestones and partnerships that shaped the year for Lucid Health Consulting and Australian healthcare.
2025 Highlights & Healthcare Policy Updates
✅HTA Framework Reform Implementation Challenges
Australia has been pursuing a major HTA Policy and Methods Review, with the Implementation Advisory Group issuing interim guidance in 2025. Reform implementation remains a priority, but progress has been gradual.
✅Cost-Effectiveness and Pricing Pressures
Pricing remains a central HTA issue:
🔹Sponsors have withdrawn applications e.g Pfizer’s abrocitinib and Eli Lilly’s lebrikizumab (Ebglyss for moderate-to-severe atopic dermatitis) due to perceived unsustainable pricing or risk-sharing requirements in HTA pricing arrangements
🔹High therapeutic value and invocative medicines recommended by the PBAC that remain unfunded on the PBS many months later, such as Heplcudex (bulevirtide) for Hepatitis D, Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS), and Tepezza (teprotumumab) for Thyroid Eye Disease
✅ Horizon Scanning
Medicines Australia’s submission to Treasury’s Economic Roundtable in July 2025 on key reform priorities. The overarching theme being the need to move beyond identifying innovations to building the structures, policies and processes required to deliver on 3 themes:
🔹Fit-for-purpose regulatory and reimbursement pathways for timely patient access
🔹The importance of a values framework and methods for health technology assessment
🔹System preparedness for personalised therapies
Our team actively participated in events locally and globally:
✴️ AusBiotech and Medicines Australia’s Women in Life Sciences Luncheon
✴️ AusMedtech 25 George Papadopoulos & Blaise Agresta led “Reimbursed & Ready Winning in the Australian Market” session
✴️ Sydney University Pharmacy School by Cicada Innovations. George returned to present on healthcare and market access strategy
✴️ ARCS Australia Annual Conference 2025
As well as hosting our stand, the team participated in the sessions:
🟢 Horizon Scanning and HTA: Past, Present and Future
🟢 Medicine Access: Innovation in Action to Drive Patient Access
🟢 Future Horizons: Professional Evolution
✴️ George Papadopoulos & Michael Aristides attended Medicines Australia’s Horizon Scanning, PharmAus 2025 and Neurological Alliance Australia’s National Action Plan Launch in Canberra
✴️ Medical Technology Association of Australia (MTAA) MedTech Conference 2025
✴️ ISPOR Europe 2025 – Michael Lees attended & we showcased our 12 abstracts with Skyward Analytics
You can view and download all 12 ISPOR Eurupe 2025 Abstracts HERE
News & Milestones
➡️ George Papadopoulos appointed to Oncothera Advocacy Board of Directors
➡️ Michael Lees joins our team
➡️ We marked a decade of Lucid Health Consulting! Founded by George Papadopoulos, Michael Aristides & Steve Crowley
Thanks to our team, clients and partners for your collaboration and support in 2025. Best wishes for the festive season and 2026 🎉
Partner with Lucid Health Consulting
At Lucid Health Consulting, we have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceuticals, biotech products, medical devices, and technologies into the Australian, New Zealand and Asia-Pacific markets.
Need support with market access or regulatory strategy in Australia, New Zealand or the APAC region?
Let’s connect. Lucid Health Consulting is ready to help you bring your pharmaceutical, medical device, or biotech product or technology, to market with confidence.
Contact and follow us to learn more about our Regulatory Affairs, Quality and Advocacy services.
🔹 Lucid Health Consulting on LinkedIn
Recent Comments